Oral Solid Dosage Manufacturing Market

Market Outlook

The global oral solid dosage manufacturing market, valued at USD 599 billion in 2025, is projected to reach USD 623 billion in 2026 and USD 861 billion by 2035, with a CAGR of 3.7% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size and Trends

• In terms of type of finished dosage form, tablets are expected to hold the highest share (close to 70%) of the market in 2026.
• Based on the type of packaging, blisters are likely to occupy the largest share of the market in 2035.
• Based on company size, large companies are anticipated to hold the highest market share (close to 75%) in 2026.
• Based on type of release mechanism, modified release segment is projected to capture the majority share of the market, by 2035.
• Based on therapeutic areas, oncological disorders is estimated to capture largest oral solid dosage manufacturing market share in 2026.
• In terms of geographical regions, North America will hold the highest market share by securing nearly 50% of the market share in future.

Market Introduction

Over the past few years, the rising complexity of active pharmaceutical ingredients (APIs) has led to the development of a myriad of novel formulations aimed at improving drug delivery to the specific site of action. Despite these advancements, oral solid dosage (OSD) forms, such as tablets and capsules continue to hold a dominant position in the global pharmaceutical market. It is important to mention that over two-thirds of the total drugs prescribed worldwide are dispensed in the form of oral solid dose pharmaceuticals. This can be attributed to various advantages offered by them, such as cost-effectiveness, better patient convenience and enhanced stability which are essential for improving medication adherence.

Driven by ongoing innovations, drug developers are focusing on the development of advanced oral formulations, such as modified disintegrating tablets (ODTs), drug device combination products and sustained- release dosage forms, that can improve API solubility and enhance bioavailability. However, the manufacturing of these oral solid doses (especially those containing highly potent APIs) is a complex and research-intensive process. It demands specialized expertise for various processes spanning from formulation development to commercial scale-up manufacturing. In order to meet the growing demand, the drug developers are relying on specialized contract service providers to navigate operational challenges, including complex formulations, strict regulations and supply chain challenges.

Market Segmentation

Based on our secondary research, we have segmented the Oral Solid Dosage Manufacturing Market into type of finished dosage form, type of packaging, type of release mechanism, company size, therapeutic area and geographical regions.

By Type of Finished Dosage Form

• Tablets
• Capsules
• Others

By Type of Packaging

• Bottles
• Blisters
• Others

By Type of Release Mechanism

• Immediate Release
• Modified Release

By Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Infectious Diseases
• Neurological Disorders
• Diabetes
• Respiratory Disorders
• Immunological Disorders
• Genetic Disorders
• Rare Diseases
• Others

By Company Size

• Small
• Mid-Sized
• Large

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

Key Market Insights

What Factors are Driving Increased Adoption of Oral Solid Formulations?

• Emergence of Virtual Pharmaceutical Companies: The growing emergence of virtual pharmaceutical oral solid dosage manufacturing companies is fueling expansion in the oral solids market. Such companies outsource key operations, including formulation, manufacturing, and testing to specialized partners, enabling accelerated development and reduced operational costs. As a result, contract development and manufacturing organizations (CDMOs) are witnessing rising demand for expertise in tablets and capsules production.
• Growing Demand for Novel Oral Solid Formulations: The oral solid dose manufacturing market is experiencing strong growth due to rising demand for innovative and more effective formulations, such as digital pills, 3D printed tablets and amorphous solid dispersions. Notably, patients and healthcare providers are consistently looking for oral solids (including tablets and capsules) with improved bioavailability, controlled release and easier administration. Pharmaceutical companies are proactively investing in cutting-edge technologies to meet these demands.

Industry Experts on Oral Solid Dosage Manufacturing Market

The market for oral solids has a transformative future and is likely to remain progressive in the future.
Shahrzad Missaghi (Senior Manager, Product Development, Colorcon), stated that, “We are aware, oral solid dosages are really on the rise, and this trend is expected to keep going past 2025 due to their ease of administration and support in patient compliance. With increasing population and people having longer lifespans, the demand keeps on increasing. At the same time, we are witnessing a big shift toward digitalization and using AI across discovery, formulation, manufacturing, and even clinical trials to make everything faster and smarter.”

The oral solid dosage contract manufacturing market report includes detailed transcripts of interviews conducted with the following individuals:

• Senior Executive Director, Global Sales & Marketing, Large Company, Japan
• Vice President, Mid-Sized Company, Sweden
• Senior Vice President, Mid-Sized Company, US
• Chief Scientific Officer, Mid-Sized Company, Finland
• Senior Management, Scientific Marketing, Very Large Company, US
• Director of Formulation and Development, Mid-Sized Company, Georgia
• Senior Vice President, Large Company, US

Market Share Insights

Which Finished Dosage Form Account for the Largest Share of Oral Solids Market?

• In 2035, the tablets segment is likely to occupy the highest (~75%) oral solid dosage manufacturing market share. Further, this segment is likely to witness a significant growth rate during the forecast period.
• This is primarily due to lower manufacturing cost and longer shelf life offered by tablets. Additionally, various delivery types (long acting drugs, such as extended release, delayed release) of tablets caters to expand their market potential.

Regional Market Analysis: Which Regions are Showing the Fastest Growth?

North America: Dominating the Market by Securing Highest Share

North America is likely to capture close to 50% of the oral solid dosage market share in 2035, owing to rising commercial demand for oral solid dosage pharmaceuticals in the US and presence of well-established oral solid dosage manufacturers in this region. Further, in recent years, many large oral solid dosage manufacturing companies within this region have expanded their capabilities to meet the growing demand in this region.

Europe: Driving the Future of Market Expansion

• In Europe, the market is likely to grow at a higher CAGR till 2035, driven by a growing investments in R&D of new drugs and stringent regulatory requirements that favor specialized manufacturers. Moreover, the growing demand for generic drugs driven by patent expirations in the region, along with the pharmaceutical industry's increasing dependence on CDMOs for cost efficiency and specialized expertise, has further accelerated the solid dose CDMO market growth.

Oral Solid Dosage Manufacturing Market: Scope of the Report

Frequently Asked Questions